Cerebral ischemia and neuroregeneration

Reggie H.C. Lee, Michelle H.H. Lee, Celeste Y.C. Wu, Alexandre Couto E Silva, Harlee E. Possoit, Tsung Han Hsieh, Alireza Minagar, Hung Wen Lin

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

Original languageEnglish (US)
Pages (from-to)373-385
Number of pages13
JournalNeural Regeneration Research
Volume13
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Brain Ischemia
Stroke
Hypothermia
Mortality
Tissue Plasminogen Activator
Melatonin
NAD
Brain Injuries
Protein Kinase C
Isoenzymes
Intercellular Signaling Peptides and Proteins
Fatty Acids
Stem Cells
Therapeutics
Morbidity
Costs and Cost Analysis
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Cerebral ischemia
  • Fatty acids
  • Melatonin
  • Neuromodulation therapy
  • Pifithrin-α
  • Protein kinase C
  • Resveratrol
  • Stem cell
  • Sympathetic nervous system
  • Traditional Chinese therapies

ASJC Scopus subject areas

  • Developmental Neuroscience

Cite this

Lee, R. H. C., Lee, M. H. H., Wu, C. Y. C., Couto E Silva, A., Possoit, H. E., Hsieh, T. H., ... Wen Lin, H. (2018). Cerebral ischemia and neuroregeneration. Neural Regeneration Research, 13(3), 373-385. https://doi.org/10.4103/1673-5374.228711

Cerebral ischemia and neuroregeneration. / Lee, Reggie H.C.; Lee, Michelle H.H.; Wu, Celeste Y.C.; Couto E Silva, Alexandre; Possoit, Harlee E.; Hsieh, Tsung Han; Minagar, Alireza; Wen Lin, Hung.

In: Neural Regeneration Research, Vol. 13, No. 3, 01.03.2018, p. 373-385.

Research output: Contribution to journalReview article

Lee, RHC, Lee, MHH, Wu, CYC, Couto E Silva, A, Possoit, HE, Hsieh, TH, Minagar, A & Wen Lin, H 2018, 'Cerebral ischemia and neuroregeneration', Neural Regeneration Research, vol. 13, no. 3, pp. 373-385. https://doi.org/10.4103/1673-5374.228711
Lee RHC, Lee MHH, Wu CYC, Couto E Silva A, Possoit HE, Hsieh TH et al. Cerebral ischemia and neuroregeneration. Neural Regeneration Research. 2018 Mar 1;13(3):373-385. https://doi.org/10.4103/1673-5374.228711
Lee, Reggie H.C. ; Lee, Michelle H.H. ; Wu, Celeste Y.C. ; Couto E Silva, Alexandre ; Possoit, Harlee E. ; Hsieh, Tsung Han ; Minagar, Alireza ; Wen Lin, Hung. / Cerebral ischemia and neuroregeneration. In: Neural Regeneration Research. 2018 ; Vol. 13, No. 3. pp. 373-385.
@article{2b3d479bba6f47e8a9129d2f387ed7ef,
title = "Cerebral ischemia and neuroregeneration",
abstract = "Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.",
keywords = "Cerebral ischemia, Fatty acids, Melatonin, Neuromodulation therapy, Pifithrin-α, Protein kinase C, Resveratrol, Stem cell, Sympathetic nervous system, Traditional Chinese therapies",
author = "Lee, {Reggie H.C.} and Lee, {Michelle H.H.} and Wu, {Celeste Y.C.} and {Couto E Silva}, Alexandre and Possoit, {Harlee E.} and Hsieh, {Tsung Han} and Alireza Minagar and {Wen Lin}, Hung",
year = "2018",
month = "3",
day = "1",
doi = "10.4103/1673-5374.228711",
language = "English (US)",
volume = "13",
pages = "373--385",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Editorial Board of Neural Regeneration Research",
number = "3",

}

TY - JOUR

T1 - Cerebral ischemia and neuroregeneration

AU - Lee, Reggie H.C.

AU - Lee, Michelle H.H.

AU - Wu, Celeste Y.C.

AU - Couto E Silva, Alexandre

AU - Possoit, Harlee E.

AU - Hsieh, Tsung Han

AU - Minagar, Alireza

AU - Wen Lin, Hung

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

AB - Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

KW - Cerebral ischemia

KW - Fatty acids

KW - Melatonin

KW - Neuromodulation therapy

KW - Pifithrin-α

KW - Protein kinase C

KW - Resveratrol

KW - Stem cell

KW - Sympathetic nervous system

KW - Traditional Chinese therapies

UR - http://www.scopus.com/inward/record.url?scp=85049833023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049833023&partnerID=8YFLogxK

U2 - 10.4103/1673-5374.228711

DO - 10.4103/1673-5374.228711

M3 - Review article

AN - SCOPUS:85049833023

VL - 13

SP - 373

EP - 385

JO - Neural Regeneration Research

JF - Neural Regeneration Research

SN - 1673-5374

IS - 3

ER -